Pseudomembranosa colitis
Keywords:
pseudomembranous colitis, Clostridium difficile.Abstract
Pseudomembranous colitis is a disease caused by Clostridium difficile (C. difficile), a Gram-positive, spore-forming bacillus, which is part of the normal intestinal microbiota in 1 to 3% of healthy adults. The first case of pseudomembranous colitis was reported in 1893, and its relationship with prolonged use of antibiotics was first described in 1974 in association with clindamycin. In recent years there has been an increase in the incidence, motivated by frequent and sometimes unordered consumption of antimicrobials. Our objective was to describe a case of a patient diagnosed with pseudomembranous colitis. A 73-year-old male patient with a history of type II DM and liver cirrhosis (CH) due to OH alcohol; previously admitted to the ICU for severe respiratory sepsis, with antimicrobial treatment regimens for 19 days, he was referred to our center 20 days after discharge due to worsening of diarrhea and abdominal pain, and a diagnosis of pseudomembranous colitis was made. Pseudomembranous colitis caused by C. difficile is an entity that should be taken into account in the diagnosis of hospitalized patients who are under antimicrobial treatment or who come from the community where they were prescribed this type of drugs.
Downloads
References
Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, & Nazeri S. “Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk factors, and therapeutic options” Scientifica vol 2014. http://dx.doi. org/10.1155/2014/916826.
Mulherin DW, Hutchison AM, Thomas GJ, Hansen RA, Childress DT. “Concordance of the SHEA/IDSA Severity classification and the ATLAS bedside scoring system in hospitalized adult patients”, Infection 2014; 42(6): 999- 1005. DOI: 10.1007/s15010-014-0671-8. Epub 2014 Aug 17.
PMID: 25129565.
Abreu AT; Velarde-Ruiz JA; Zavala-Solares MR et al: Consenso sobre prevención, diagnóstico y tratamiento de la infección por Clostridium Diffíle.Rev Gastroenterología de México. 2019;84(2):204-219. https://doi.org/10.1016/j.rgmx.2018.12.001
Martínez-Rodríguez AA, Estrada-Hernández LO, Tomé-Sandoval P, Salazar-Salinas J. Diarrea por Clostridium difficile en pacientes hospitalizados. Med Int Méx. 2018 ene;34(1):9-18.DOI: https://doi.org/10.24245/mim.v34i1.1921
Tartabull-Poutriel K, Toledo-Cabarcos Y, Nicolau-Pestana E. Colitis pseudomembranosa: a propósito de un caso. Arch Méd Camagüey [Internet]. 2019 [citado 22 Abr 2021];, 23(2):[aprox. 5 p.]. Disponible en: http://revistaamc.sld.cu/index.php/amc/article/view/6268
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al, “Clinical practice guidelines for clostridium difficile Infection in adults: 2010 update by the Society for Health care epidemiology in America (SHEA), and the Infectious diseases Society of America (IDSA); Infect Control Hosp Epidemiol 2010; 31 (5): 431-455. doi: 10.1086/651706. PMID: 20307191.
Gilbreath J, Verma P, Abbott A. N, & Butler-Wu S, “Comparison of the verigene Clostridium difficile, Simplexa Clostridium difficile Universal direct, BD MAX Cdiff, and Xpert Cdifficile assays for the detection of toxigenic C. difficile” Diagn Microbiol Infect Dis 2014, http://dx.doi.org/10.1016/j.diagmicrobio.2014.06.00.
Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiologyof community associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med [Internet]. 2013 [citado 05 Mar 2019];173(14):[aprox. 9 p.]. Disponible en: https://jamanetwork.com/journals/ jamainternalmedicine/fullarticle/10.1001/ jamainternmed.2013.7056
Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. Published 2016 Apr 7. doi:10.1038/nrdp.2016.20
Sanguina M, Pineda GA, Benítez PE. Colitis pseudomembranosa por Clostridium difficile. Rev. virtual Soc. Parag. Med. Int. [Internet]. 2018 Mar [citado 2021 Abr 22] ; 5( 1 ): 87-93. Disponible en: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S2312-38932018000100087&lng=es. Epub 01-Mar-2018. https://doi.org/10.18004/rvspmi/2312-3893/2018.05(01)87-093.
Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014 Nov;69(11):2892-900. doi: 10.1093/jac/dku261. Epub 2014 Jul 28. PMID: 25074856.
Alvarez-Hernandez DA, Gonzalez-Chavez AM, Gonzalez-Hermosillo-Cornejo D, et al. Present and past perspectives on Clostridium difficile infection. Rev Gastroenterol Mex. 2018; 83:41-50
Debast S. B, Bauer M. P, & Kuijper J, “European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection” Clinical Microbiology and Infection 2014; 21 (suppl 2): 1-26. DOI:https://doi.org/10.1111/1469-0691.12418
Mcdonald MC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE et al. clinical practice guidelines for clostridium difficile infection in adults and children: 2017 Update by the Infectious diseases society of america (Idsa) and society for Healthcare epidemiology of america (sHea). Clin Infect Dis. 2018; 66 (7): e1-e48. doi: 10.1093/cid/cix1085. PMID: 29462280; PMCID: PMC6018983.
Ochoa-Hein, E., Sifuentes-Osornio, J., Ponce de León-Garduño, A., Torres-González, P., Granados-García, V., & Galindo-Fraga, A. (2018). Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study. PloS one, 13(5), e0198212. https://doi.org/10.1371/journal.pone.0198212
Thomas A, Khan F, Uddin N, Wallace M, “Tigecycline for severe Clostridium difficile infections” Int J Infec Dis 2014, http://dx.doi.org/10.1016/j. ijid.2014.04.025.
Khoruts A, & Weingarden A. “Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology” Immunology letters 2014; http://dx.doi.org/10.1016/j.imlet.2014.07.016.
Cammarota G, Ianiro G, & Gasbarrini A. “Fecal Microbiota Transplantation for the treatment of Clostridium difficile infection: a systematic review”, J clin Gastroenterol 2014; 48: 693-702. DOI: 10.1097/mcg.0000000000000046.
Zainah H, Hassan M, Shiekh- Sroujieh L, Hassan S, Alangaden G & Ramesh M. “Intestinal Microbiota Transplantation, a simple and effective treatment for severe and Refractory Clostridium difficile Infection” Dig Dis Sci 2014; http://dx.doi.org/10.1007/s10620-014-3296.
Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. “Fecal Microbiota transplant for treatment of Clostridium difficile infection infection in immunocompromised patients” Am J Gartroenterol 2014; 109: 1065-1071.
Mizahri A, Collignon A, & Péchiné S.” Passive and Active Immunization strategies against Clostridium difficile infections: state of Art” Anaerobe 2014, http://dx.doi.org/10.1016/j.anaerobe.2014.07.006.
Chen Y, Glass K, Liu B, Korda RJ, Riley TV, Kirk MD. Burden of Clostridium difficile infection: Associated hospitalization in a cohort of middle-aged and older adults. Am J Infect Control. 2017 May 1;45(5):508-511. doi: 10.1016/j.ajic.2016.12.006. Epub 2017 Jan 13. PMID: 28089675.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Archivos Cubanos de Gastroenterolog?a
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
La revista reconoce a las personas que firman como autores siempre y cuando estos cumplan con los criterios establecidos universalmente para los autores de los art?culos cient?ficos. Regularmente se solicitar? a los autores de art?culos originales, env?en la declaraci?n de autor?a firmada por cada uno de ellos y donde se explique su rol dentro de la investigaci?n. El comit? editorial se reserva el derecho de aceptar determinados autores en relaci?n con el rol declarado y la envergadura de la investigaci?n.
Esta revista protege los Derechos de autor desde el mismo momento en que se realiza el env?o. Sin embargo, cede parte de los derechos patrimoniales de autor al exhibir una licencia Creative Commons 4.0 (cc-by-nc), que permite el uso de la obra para compartir (copiar y redistribuir el material en cualquier medio o formato) y adaptar (remezclar, transformar y construir a partir del material) siempre y cuando se haga menci?n exclusiva a la publicaci?n en la revista como fuente primaria. ?Sin embargo, no podr? comercializar con ella.
?
